An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin and thymosin beta-4. The panel turned down emideltide. Shares of HIMS climbed overnight following the committee's endorsement of four peptides. Bachem shares held steady after the vote. A recent study indicated peptides may assist with combating antibiotic-resistant bacteria. Meanwhile, Kennedy called for expanded access to controversial peptides, calling for slackened rules. The vote reflects a broader shift in how policymakers view custom-mixed peptide therapies, which have drawn increasing interest from patients seeking alternatives to traditional drugs. Investigators say peptide treatments could alter approaches to stubborn infections, though concerns about safety persist. The committee's endorsement of six peptides opens the door for more expanded prescribing, even as skeptics warn of long-term evidence. Sector observers note that peptide-focused companies may see greater investor attention following the panel's decision. The rejection of emideltide, meanwhile, underscores the FDA's cautious stance on some peptide candidates.